Bright Minds, Firefly Team Up to Analyze Data of Phase 2 Study of BMB-101 to Treat Epilepsy; Shares Rise

MT Newswires Live10-21

Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tolerability and efficacy of BMB-101 to treat absence epilepsy and developmental epileptic encephalopathy.

The trial is expected to enroll 20 adults from 18 to 65 years old, Bright Minds said.

Bright Minds and Firefly have previously collaborated to analyze data from the phase 1 trial of BMB-101 using Firefly's BNA technology platform, the company said.

"This compound is not only poised to make a significant impact in both the [developmental epileptic encephalopathy] and absence epilepsy communities, but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance," said Ian McDonald, Bright Minds chief executive .

Bright Minds shares rose 24% in early trading, while Firefly was up 17%.

Price: 58.74, Change: +11.53, Percent Change: +24.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477863045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-21 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477863045","market":"nz","top_or_hot":-1,"title":"Bright Minds, Firefly Team Up to Analyze Data of Phase 2 Study of BMB-101 to Treat Epilepsy; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tolerability and efficacy of BMB-101 to treat absence epilepsy and developmental epileptic encephalopathy.</p><p>The trial is expected to enroll 20 adults from 18 to 65 years old, Bright Minds said.</p><p>Bright Minds and Firefly have previously collaborated to analyze data from the phase 1 trial of BMB-101 using Firefly's BNA technology platform, the company said.</p><p>\"This compound is not only poised to make a significant impact in both the [developmental epileptic encephalopathy] and absence epilepsy communities, but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance,\" said Ian McDonald, Bright Minds chief executive .</p><p>Bright Minds shares rose 24% in early trading, while Firefly was up 17%.</p><p>Price: 58.74, Change: +11.53, Percent Change: +24.42</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bright Minds, Firefly Team Up to Analyze Data of Phase 2 Study of BMB-101 to Treat Epilepsy; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBright Minds, Firefly Team Up to Analyze Data of Phase 2 Study of BMB-101 to Treat Epilepsy; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-21 21:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TISI","symbol_name":"Team Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477863045","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477863045","pubTimestamp":1729518308,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tole","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TISI":"Team Inc","DRUG":"Bright Minds Biosciences Inc","AIFF":"Firefly Neuroscience, Inc."},"translate_title":"Bright Minds、Firefly联手分析BMB-101治疗癫痫的2期研究数据；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TISI":1,"AIFF":0.9,"DRUG":0.9},"content_text":"Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tolerability and efficacy of BMB-101 to treat absence epilepsy and developmental epileptic encephalopathy.The trial is expected to enroll 20 adults from 18 to 65 years old, Bright Minds said.Bright Minds and Firefly have previously collaborated to analyze data from the phase 1 trial of BMB-101 using Firefly's BNA technology platform, the company said.\"This compound is not only poised to make a significant impact in both the [developmental epileptic encephalopathy] and absence epilepsy communities, but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance,\" said Ian McDonald, Bright Minds chief executive .Bright Minds shares rose 24% in early trading, while Firefly was up 17%.Price: 58.74, Change: +11.53, Percent Change: +24.42","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477863045"}